Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)

Second-line treatment with karenitecin was tolerable with reversible bone marrow suppression as the major toxicity. The partial response rates, median survival times, and 1-year survival rates in the relapsed and refractory subgroups are comparable to overall second-line outcomes for other agents considered active in this clinical setting.